Bereich
Stabsdienste Departement Innere Medizin
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PloS one 2022; 17:e0268545.
10.06.2022Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
10.06.2022PloS one 2022; 17:e0268545
Adam Roman, Tibau Ariadna, Molto Valiente Consolación, Seruga Bostjan, Ocana Alberto, Amir Eitan, Templeton Arnoud J
Comparison of ratings with OLUtool Onko version 2.0 (v2) and version 3.2 (v3) of cancer drugs approved since 2010 in Switzerland
Adam R (2020). Comparison of ratings with OLUtool Onko version 2.0 (v2) and version 3.2 (v3) of cancer drugs approved since 2010 in Switzerland.
05.10.2020Comparison of ratings with OLUtool Onko version 2.0 (v2) and version 3.2 (v3) of cancer drugs approved since 2010 in Switzerland
05.10.2020Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
Adam Roman
Clinical benefit of cancer drugs approved in Switzerland during the last decade
Adam R (2020). Clinical benefit of cancer drugs approved in Switzerland during the last decade.
01.09.2020Clinical benefit of cancer drugs approved in Switzerland during the last decade
01.09.2020ESMO Congress 2020
Adam Roman
Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression.
Adam R, Diez-Gonzalez L, Ocana A, Seruga B, Amir E, Templeton A. Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. Exp Mol Pathol 2017; 102:455-474.
12.05.2017Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression.
12.05.2017Exp Mol Pathol 2017; 102:455-474
Adam Roman, Diez-Gonzalez Laura, Ocana Alberto, Seruga Bostjan, Amir Eitan, Templeton Arnoud J